(News Bulletin 247)-The nano-medicine specialist announced first positive results for phase I study JNJ-1900 evaluating in patients with skin melanoma. On the Paris Stock Exchange, the action bounces.

Nanobiotix is ​​progressing strongly this Thursday, September 18, at the Paris Stock Exchange, and leaps by 15% shortly before 3 p.m. The specialist in nano-medicine thus returns above 10 euros, in volumes fed for the company with more than 940,000 titles exchanged since the opening.

This net rebound in the title at more explored levels since October 2021 is to be put in perspective with the last announcement of the company which relies on the physical properties (therefore indifferent to the biological variability from one individual to another) of nanoparticles to improve the efficiency of radiotherapies.

Preliminary effectiveness signals

Nanobiotix has announced new results in patients with skin melanoma, from the study during phase I (early phase of clinical trials) “study 1100”, during the Immunorad 2025 scientific congress which is currently being held in Paris.

This study assesses JNJ-1900 (NBTXR3) in combination with an immune control point inhibitor (Pembrolizumab or Nivolumab) in patients with advanced cancer. All patients have received a single intratomoral injection of JNJ-1900 (NBTXR3) followed by radiotherapy and then treatment with anti-PD-1.

The results presented by Nanobiotix have shown that JNJ-1900 (NBTXR3) has shown preliminary efficiency signals in 19 patients evaluable for tumor response and two other patients could not be assessed due to the lack of post-treatment imaging.

Of these 19 patients, the objective response rate (orr) reached 47.4 %, and the rate of disease control (DCR) 78.9 %, while the overall median survival (MOS) was 14.6 months (n = 21). In comparison, Oddo BHF notes that “Post Yervoy (Ipilimumab), the Keynote002 trial, evaluating Keytruda, had shown a median OS of 14.7 months for an orr of only 25%”.

At the level of the safety profile, the feasibility of the injection was confirmed at the recommended dose for phase II (intermediate clinical step) (33 % of the tumor volume). Stifel specifies for its part that the safety remains consistent with the previous data since the recommended dose (RP2D) has been validated at 33% of the tumor volume and the feasibility of the injection is confirmed.

Promising results

Biologically, Invest Securities notes that observations are in line with clinical results. “A link has been observed between the depth of the local response and the systemic response, suggesting possible activation or reactivation of the immune response,” adds the design office.

“Briefly, this phase I is a success showing both a favorable security profile (which was not necessarily a subject) and signals of early efficiency in a heavily pre -pruned population”, summarizes Oddo BHF, which judges these results “promising”.

For the previously quoted financial intermediary, these results therefore support the potential of NBTXR3 and support the thesis that NBTXR3 could become a “therapy backbone” (essential therapy) in oncology.

“These first results in advanced melanoma are convincing and show on the one hand an efficiency of the product and very good safety of employment in comparison with Amtagvi (a cell therapy developed by Iovance Biotherapeutics, Editor’s note),” he says.

The Risk/Reward (Risk/Profit Report) on Nanobiotix therefore seems to us always attractive on these valuation levels, believes Oddo BHF.

“The next catalyst which could allow a massive revaluation (revaluation) of the title should be the publication of the intermediate results of phase 3 Nanoray-312 expected mid 2026”, specifies the financial intermediary which confirms its opinion to “outperformance” on the title as well as course objective at 10 euros.